CVS Health Corporation $CVS Position Lowered by Colrain Capital LLC

Colrain Capital LLC lessened its stake in CVS Health Corporation (NYSE:CVS) by 6.6% during the 4th quarter, Holdings Channel.com reports. The institutional investor owned 122,480 shares of the pharmacy operator’s stock after selling 8,725 shares during the quarter. CVS Health accounts for approximately 5.3% of Colrain Capital LLC’s holdings, making the stock its 7th largest position. Colrain Capital LLC’s holdings in CVS Health were worth $9,720,000 at the end of the most recent quarter.

Several other hedge funds have also recently modified their holdings of CVS. Kingsview Wealth Management LLC increased its position in CVS Health by 316.2% during the third quarter. Kingsview Wealth Management LLC now owns 104,432 shares of the pharmacy operator’s stock valued at $7,873,000 after acquiring an additional 79,340 shares during the last quarter. Intech Investment Management LLC increased its position in CVS Health by 50.3% during the third quarter. Intech Investment Management LLC now owns 86,564 shares of the pharmacy operator’s stock valued at $6,526,000 after acquiring an additional 28,953 shares during the last quarter. Assetmark Inc. increased its position in CVS Health by 12.5% during the third quarter. Assetmark Inc. now owns 678,558 shares of the pharmacy operator’s stock valued at $51,156,000 after acquiring an additional 75,603 shares during the last quarter. Hamlin Capital Management LLC bought a new position in CVS Health during the fourth quarter valued at $160,844,000. Finally, Cresset Asset Management LLC increased its position in CVS Health by 56.8% during the third quarter. Cresset Asset Management LLC now owns 35,481 shares of the pharmacy operator’s stock valued at $2,675,000 after acquiring an additional 12,849 shares during the last quarter. Hedge funds and other institutional investors own 80.66% of the company’s stock.

CVS Health Trading Up 2.4%

NYSE CVS opened at $100.38 on Friday. The company’s 50-day moving average price is $86.32 and its 200-day moving average price is $80.63. The company has a current ratio of 0.87, a quick ratio of 0.66 and a debt-to-equity ratio of 0.78. The stock has a market cap of $128.08 billion, a PE ratio of 44.22, a PEG ratio of 0.96 and a beta of 0.62. CVS Health Corporation has a 12 month low of $58.50 and a 12 month high of $100.55.

CVS Health (NYSE:CVS) last posted its quarterly earnings results on Wednesday, May 6th. The pharmacy operator reported $2.57 EPS for the quarter, topping analysts’ consensus estimates of $2.21 by $0.36. The firm had revenue of $100.43 billion for the quarter, compared to analysts’ expectations of $94.99 billion. CVS Health had a net margin of 0.72% and a return on equity of 11.88%. The business’s revenue for the quarter was up 6.2% on a year-over-year basis. During the same period in the prior year, the business posted $2.25 earnings per share. CVS Health has set its FY 2026 guidance at 7.300-7.500 EPS. Equities research analysts forecast that CVS Health Corporation will post 7.44 earnings per share for the current year.

CVS Health Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Monday, May 4th. Shareholders of record on Thursday, April 23rd were issued a dividend of $0.665 per share. This represents a $2.66 annualized dividend and a yield of 2.6%. The ex-dividend date was Thursday, April 23rd. CVS Health’s dividend payout ratio is presently 117.18%.

Insider Activity

In other CVS Health news, Director Larry Robbins sold 1,983,538 shares of the stock in a transaction dated Tuesday, May 19th. The shares were sold at an average price of $94.45, for a total transaction of $187,345,164.10. Following the transaction, the director directly owned 6,213,261 shares in the company, valued at $586,842,501.45. This represents a 24.20% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Tilak Mandadi sold 69,551 shares of the stock in a transaction dated Friday, May 8th. The stock was sold at an average price of $89.58, for a total transaction of $6,230,378.58. Following the transaction, the executive vice president owned 10,133 shares in the company, valued at approximately $907,714.14. The trade was a 87.28% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders have sold 3,441,551 shares of company stock worth $323,703,977. 0.85% of the stock is owned by company insiders.

Key CVS Health News

Here are the key news stories impacting CVS Health this week:

• Positive Sentiment: CVS Health said it is using Fluency’s enterprise AI platform to move autonomous agents from pilot projects into production, a sign it is working to cut administrative costs and improve workflow efficiency across the business. CVS is Using Fluency to Close Enterprise AI Deployment Gap
• Positive Sentiment: Aetna launched “Mental Health on Demand,” which gives members real-time access to care and ongoing support; the company highlighted very fast clinician connection times, underscoring stronger service delivery and potentially better member engagement. Aetna Launches Aetna Mental Health on Demand To Provide Real Time Access to Care and Ongoing Support
• Positive Sentiment: CVS Caremark expanded coverage options for GLP-1 weight-loss medications, a move that may support affordability for members while strengthening the company’s position in a fast-growing and closely watched drug category. CVS Caremark Delivers Affordability and Access to GLP-1 Weight Management Medications With Expanded Coverage Options

Wall Street Analysts Forecast Growth

A number of research analysts have weighed in on CVS shares. Piper Sandler reiterated an “overweight” rating and set a $113.00 price objective on shares of CVS Health in a research report on Monday, June 1st. Argus boosted their price objective on shares of CVS Health from $90.00 to $104.00 and gave the company a “buy” rating in a research report on Thursday, May 14th. Deutsche Bank Aktiengesellschaft boosted their price objective on shares of CVS Health from $88.00 to $92.00 and gave the company a “buy” rating in a research report on Thursday, May 7th. Robert W. Baird upped their price target on shares of CVS Health from $92.00 to $94.00 and gave the stock an “outperform” rating in a report on Wednesday, April 15th. Finally, Truist Financial upped their price target on shares of CVS Health from $102.00 to $108.00 and gave the stock a “buy” rating in a report on Monday, June 1st. Twenty-two research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company’s stock. Based on data from MarketBeat, CVS Health presently has an average rating of “Moderate Buy” and an average price target of $100.68.

CVS Health Profile

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over?the?counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in?store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk?in medical clinics and HealthHUB locations that offer expanded clinical services.